Detailed company information
Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry. This system is specifically applied to the field of proteomics, paving the way for next-generation protein sequencing. Established in 2013, Quantum-Si's headquarters are located in Guilford, Connecticut.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 13, 2026
Earnings Transcript for 2026 - Q1Released: May 07, 2026
Earnings Transcript for 2025 - Q4Released: Mar 04, 2026
Earnings Transcript for 2025 - Q3Released: Nov 05, 2025
Earnings Transcript for 2025 - Q2Released: Aug 05, 2025
Earnings Transcript for 2025 - Q1Released: May 15, 2025
Earnings Transcript for 2024 - Q4Released: Mar 03, 2025
Earnings Transcript for 2024 - Q3Released: Nov 12, 2024
Earnings Transcript for 2024 - Q2Released: Aug 07, 2024
Earnings Transcript for 2024 - Q1Released: May 09, 2024
Earnings Transcript for 2023 - Q4Released: Feb 29, 2024
Earnings Transcript for 2023 - Q3Released: Nov 09, 2023
Earnings Transcript for 2023 - Q2Released: Aug 07, 2023
Earnings Transcript for 2023 - Q1Released: May 11, 2023
Earnings Transcript for 2022 - Q4Released: Mar 06, 2023
Earnings Transcript for 2022 - Q3Released: Nov 07, 2022
Earnings Transcript for 2022 - Q2Released: Aug 08, 2022
Earnings Transcript for 2022 - Q1Released: May 09, 2022
Earnings Transcript for 2021 - Q4Released: Feb 28, 2022
Earnings Transcript for 2021 - Q3Released: Nov 11, 2021
Earnings Transcript for 2021 - Q2Released: Aug 16, 2021
HRTX Heron Therapeutics, Inc.
Quantum-Si's 2025 Q4 earnings reveal that while the Proteus platform is set for a late 2026 launch with commercialization ramping in 2027, management has not provided explicit unit sales guidance for 2027. The focus remains on preparatory market activities and staged adoption.
Read post
Dafinchi
